Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis (Q38667430)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

5 September 2017

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis (English)

1 reference

Europe PubMed Central

5 September 2017

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

0 references

Désirée van der Heijde

4

object named as

Désirée van der Heijde

0 references

Robert Landewé

3

object named as

Robert Landewé

1 reference

Europe PubMed Central

5 September 2017

Maxime Dougados

5

object named as

Maxime Dougados

1 reference

Europe PubMed Central

5 September 2017

object named as

Laure Gossec

10

0 references

object named as

Sofia Ramiro

1

0 references

2

object named as

Josef S Smolen

1 reference

Europe PubMed Central

5 September 2017

Maurizio Cutolo

8

object named as

Maurizio Cutolo

1 reference

Europe PubMed Central

5 September 2017

7

object named as

Maarten de Wit

1 reference

Europe PubMed Central

5 September 2017

author name string

Susan Oliver

9

1 reference

Europe PubMed Central

5 September 2017

language of work or name

0 references

publication date

11 December 2015

1 reference

Europe PubMed Central

5 September 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

5 September 2017

75

1 reference

Europe PubMed Central

5 September 2017

490-498

1 reference

Europe PubMed Central

5 September 2017

3

1 reference

Europe PubMed Central

5 September 2017

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised pla

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Clinical outcomes in psoriatic arthritis: A systematic literature review

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208466

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2015-208466

1 reference

Europe PubMed Central

5 September 2017

10.1136/ANNRHEUMDIS-2015-208466

0 references

Dimensions Publication ID

0 references

Microsoft Academic ID

0 references

1 reference

Europe PubMed Central

5 September 2017

2-s2.0-84960193219

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38667430&oldid=1775759073"